IRIS
TAGLIAFERRI, PIEROSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.748
AS - Asia 2.272
EU - Europa 2.112
SA - Sud America 157
AF - Africa 36
Continente sconosciuto - Info sul continente non disponibili 24
OC - Oceania 20
Totale 9.369
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.512
SG - Singapore 1.526
IT - Italia 984
CN - Cina 380
SE - Svezia 308
GB - Regno Unito 280
DE - Germania 208
CA - Canada 203
BR - Brasile 130
IN - India 123
FI - Finlandia 87
NL - Olanda 46
HK - Hong Kong 35
PK - Pakistan 25
RU - Federazione Russa 25
JO - Giordania 24
RO - Romania 24
ES - Italia 23
EU - Europa 22
FR - Francia 22
UA - Ucraina 21
ID - Indonesia 18
BD - Bangladesh 17
JP - Giappone 17
MX - Messico 17
IR - Iran 16
ZA - Sudafrica 16
AU - Australia 15
SA - Arabia Saudita 14
AT - Austria 13
CZ - Repubblica Ceca 13
IQ - Iraq 13
TR - Turchia 13
PL - Polonia 12
LT - Lituania 9
PT - Portogallo 9
CL - Cile 8
EE - Estonia 8
VN - Vietnam 8
AE - Emirati Arabi Uniti 7
EG - Egitto 7
EC - Ecuador 6
IE - Irlanda 6
MA - Marocco 5
MY - Malesia 5
CU - Cuba 4
CY - Cipro 4
KR - Corea 4
NZ - Nuova Zelanda 4
PH - Filippine 4
TW - Taiwan 4
BG - Bulgaria 3
CO - Colombia 3
ET - Etiopia 3
GT - Guatemala 3
HN - Honduras 3
IL - Israele 3
LB - Libano 3
LK - Sri Lanka 3
NG - Nigeria 3
PE - Perù 3
TT - Trinidad e Tobago 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CH - Svizzera 2
HR - Croazia 2
HU - Ungheria 2
PS - Palestinian Territory 2
AL - Albania 1
AR - Argentina 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BO - Bolivia 1
CR - Costa Rica 1
GE - Georgia 1
GR - Grecia 1
JM - Giamaica 1
KE - Kenya 1
KI - Kiribati 1
NI - Nicaragua 1
NP - Nepal 1
OM - Oman 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 9.369
Salva come PNG Salva come JPEG
Città #
Chandler 807
Singapore 638
Santa Clara 397
Milan 351
Lawrence 343
Princeton 343
Chicago 241
London 212
Wilmington 185
Ottawa 160
Munich 156
Ashburn 138
Des Moines 115
Catanzaro 105
Turku 64
Beijing 51
Shanghai 43
Los Angeles 41
Boardman 40
Rome 35
Pune 34
Norwalk 33
Guangzhou 30
Redmond 27
Hong Kong 25
San Francisco 24
The Dalles 24
Helsinki 23
Naples 23
New York 22
Brooklyn 21
Redwood City 21
São Paulo 20
Amman 16
Parma 16
San Nicola Manfredi 16
Shenzhen 16
Dallas 13
Carbonia 12
Chennai 12
Cosenza 12
Horia 12
Montreal 12
Palermo 12
Reggio Calabria 12
Seattle 12
Spezzano della Sila 12
Warsaw 12
Augusta 11
Hanover 11
Mountain View 11
Olomouc 11
Phoenix 11
Toronto 11
Atlanta 10
Columbus 10
Manchester 10
West Jordan 10
Delhi 9
Jiaxing 9
Stockholm 9
Tokyo 9
Afragola 8
Ercolano 8
Irbid 8
Madrid 8
Mexico City 8
Santo Stefano di Rogliano 8
Washington 8
Amsterdam 7
Boston 7
Council Bluffs 7
Kaunas 7
Leawood 7
Rogliano 7
Settingiano 7
Ankara 6
Aversa 6
Cape Town 6
Catania 6
Denver 6
Jeddah 6
Las Vegas 6
Melito di Porto Salvo 6
Moscow 6
Nanjing 6
Riyadh 6
Secaucus 6
Timisoara 6
Wuxi 6
Xi'an 6
Zhengzhou 6
Andover 5
Cardiff 5
Charlotte 5
Frankfurt am Main 5
Islamabad 5
Johannesburg 5
Lucknow 5
Meppel 5
Totale 5.372
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 352
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 84
miR-22 suppresses DNA ligase III addiction in multiple myeloma 84
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 78
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 68
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 62
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 62
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 59
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 56
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 54
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 53
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 51
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 50
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 50
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 50
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 49
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 48
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 48
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 46
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 45
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 45
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 44
CARDIOVASCULAR MONITORING OF DRUG-RESISTANT LYMPHOMA PATIENTS TREATED WITH EPOCH CHEMOTHERAPY PLUS HIGH-DOSE VERAPAMIL IN CONTINUOUS-INFUSION 44
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 44
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 43
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 43
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 42
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 42
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 41
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 41
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 40
Mir-34: a new weapon against cancer? 40
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 40
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 40
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 40
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 39
Mir-221/222 are promising targets for innovative anticancer therapy 39
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells 39
Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration - Antitumor activity and immunomodulatory effects 39
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 39
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 39
COOPERATIVE ANTIPROLIFERATIVE EFFECTS OF 8-CHLORO-CYCLIC AMP AND 528 ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODY ON HUMAN CANCER-CELLS 38
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation 38
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 38
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 38
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 38
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 37
Mmrf-commpass data integration and analysis for identifying prognostic markers 37
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 36
REVERSAL OF ADRIAMYCIN RESISTANCE BY RECOMBINANT ALPHA-INTERFERON IN MULTIDRUG-RESISTANT HUMAN COLON-CARCINOMA LOVO-DOXORUBICIN CELLS 36
2 CLASSES OF CAMP ANALOGS SYNERGISTICALLY INHIBIT P21 RAS PROTEIN-SYNTHESIS AND PHENOTYPIC TRANSFORMATION OF NIH/3T3 CELLS TRANSFECTED WITH HA-MUSV DNA 36
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 36
5-AZA-2'-DEOXYCYTIDINE INDUCES GROWTH-INHIBITION AND UP-REGULATION OF EPIDERMAL GROWTH-FACTOR RECEPTOR ON HUMAN EPITHELIAL CANCER-CELLS 36
A35 SINGLE NUCLEOTIDE POLYMORPHISMS OF THE ABCG1 AND ABCC5 TRANSPORTER GENES CORRELATE TO IRINOTECAN-ASSOCIATED GASTROINTESTINAL TOXICITY IN COLORECTAL CANCER PATIENTS AS ASSESSED BY DMET MICROARRAY PROFILING 36
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 36
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 36
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 36
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 35
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 35
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC) 35
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 35
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients 35
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? 35
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 35
Proteomic profiling of inherited breast cancer: Identification of molecular targets for early detection, prognosis and treatment, and related bioinformatics tools 35
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 35
A PH-DEPENDENT DIFFERENTIAL CYTO-TOXICITY OF OUABAIN FOR HUMAN-CELLS TRANSFORMED BY CERTAIN ONCOGENES 34
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives 34
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 34
Second-line treatment of non-small cell lung cancer by biweekly gemcitabine and docetaxel plus /- granulocyte-macrophage colony stimulating factor and low dose aldesleukine 34
IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells 34
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 34
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 34
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 34
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 34
Distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a pd-1 immune checkpoint blockade: A real-world retrospective multi-institutional analysis 34
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 33
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 33
Slow release lanreotide in combination with interferon-α2b in the treatment of symptomatic advanced medullary thyroid carcinoma 33
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma 33
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 33
Integration of DNA Microarray with Clinical and Genomic Data 33
Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: Preclinical and clinical implications 32
Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment 32
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of cancer 32
SITE-SELECTIVE CAMP ANALOGS AT MICROMOLAR CONCENTRATIONS INDUCE GROWTH ARREST AND DIFFERENTIATION OF ACUTE PROMYELOCYTIC, CHRONIC MYELOCYTIC, AND ACUTE LYMPHOCYTIC HUMAN-LEUKEMIA CELL-LINES 32
Effects of transforming growth factor-β and budesonide on mitogen-activated protein kinase activation and apoptosis in airway epithelial cells 32
The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis. 31
EGF-R small inhibitors and anti-EGF-R antibodies: Advantages and limits of a new avenue in anticancer therapy 31
miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling. 31
miR-221/222 inhibitors for the treatment of multiple myeloma 31
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 31
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 31
The farnesyltransferase inhibitor R115777 (ZARNESTRA®) enhances the pro-apoptotic activity of interferon-α through the inhibition of multiple survival pathways 30
8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor 30
Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy 30
Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: Experimental models and translational issues 30
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 30
LOW-DOSE DOPAMINE INDUCES EARLY RECOVERY OF RECOMBINANT INTERLEUKIN-2 IMPAIRED RENAL-FUNCTION 30
Proteomic pattern of BRCA1-deficient and reconstituted HCC1937 breast cancer cells: correlation with sensitivity profile to mitotic spindle poisoning drugs 30
Totale 4.309
Salva come PNG Salva come JPEG
Categoria #
all - tutte 142.192
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 142.192
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021387 63 4 10 18 45 31 33 16 48 69 44 6
2021/2022952 17 6 12 278 50 19 31 197 95 91 144 12
2022/20232.556 706 75 83 206 274 227 13 161 387 160 214 50
2023/20241.353 310 134 115 93 94 320 40 53 15 46 61 72
2024/20254.071 551 241 183 127 225 512 108 153 477 247 415 832
2025/202667 67 0 0 0 0 0 0 0 0 0 0 0
Totale 9.652